Skip to content

The German Patient Blood Management Network

Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02147795
Enrollment
1000000
Registered
2014-05-28
Start date
2012-01-31
Completion date
2025-12-31
Last updated
2023-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical Safety of a PBM Program

Keywords

Patient Blood Management, Red Blood Cell Transfusion Practice, Patient Safety, Anemia, Clinical Outcome, perioperative care

Brief summary

* This epidemiological trial will determine whether the implementation of a PBM program is safe and effective in terms of clinical outcome compared to a pre-implementation cohort * Primary endpoint is a composite outcome comprising in-hospital myocardial infarction, stroke, acute renal failure, death of any cause, pneumonia and sepsis until discharge from hospital in patients before and after implementation of the PBM program. * Secondary endpoints are the length of stay on the intensive care unit, total hospital stay and the quantitative utilization of allogeneic RBC units, platelet concentrates, other blood products (e.g. fresh frozen (therapeutic) plasma), coagulations factors, and cell saver systems during hospital stay. * The primary aim is to prove non-inferiority of the intervention (PBM) group when compared with the control group stratified by center.

Detailed description

Background: The transfusion of allogeneic red blood cell units might be associated with increased morbidity and mortality due to infectious, immunological, pulmonary and thromboembolic complications. However, transfusion practice currently varies significantly between hospitals and even between physicians and Patient Blood Management programs have not been implemented nationwide in Germany yet. Patient Blood Management (PBM) concepts aim to identify and optimize patients at risk of allogeneic blood transfusions, to promote blood-sparing techniques and restrictive transfusion practices. A rational use of red blood cell concentrates and safe clinical transfusion practice is mandatory. The purpose of the German PBM network is to evaluate the safety of a standardized, evidence-based Patient Blood management concept. Study Design and Methods: This epidemiological study is a follow-up of a study that is already being carried out in four German university hospitals. This new prospective, multi-centre trial comprises approximately 20 different hospitals of varying size and levels of patient care. A patient-centred, evidence-based Patient Blood Management program will be enrolled in each of these hospitals reforming the care of adult patients undergoing any type of surgery. This PBM program includes the following three main pillars: 1) preoperative optimization of hemoglobin levels in high-risk patients with anaemia, 2) standardization of transfusion practice and transfusion triggers according to evidence-based guidelines and 3) alternatives to transfusion of allogeneic RBC concentrates and blood-sparing techniques (like routine use of cell saver systems, point-of-care diagnostics, optimized coagulation management, restrictive blood sampling).

Interventions

None listed

Sponsors

Vifor Pharma
CollaboratorINDUSTRY
B. Braun Melsungen AG
CollaboratorINDUSTRY
CSL Behring
CollaboratorINDUSTRY
Fresenius Kabi
CollaboratorINDUSTRY
Johann Wolfgang Goethe University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* all surgeries with a general or local anaesthetic * minimum hospital stay of 24 h * ≥ 18 years

Exclusion criteria

* \< 18 years * ophthalmologic or dermatologic or outpatient surgery * all non-surgical anesthetic procedures

Design outcomes

Primary

MeasureTime frameDescription
Composite Outcome for and after PBM programParticipants will be followed for the duration of hospital stay, an expected average of 2 weekscomposite outcome comprising in-hospital myocardial infarction, stroke, acute renal failure, death of any cause, pneumonia and sepsis until discharge from hospital in patients before and after implementation of the PBM program

Secondary

MeasureTime frameDescription
Length of stayParticipants will be followed for the duration of hospital stay, an expected average of 2 weekslength of stay on the intensive care unit, total hospital stay
haemotherapyParticipants will be followed for the duration of hospital stay, an expected average of 2 weeksthe quantitative utilization of allogeneic RBC units, platelet concentrates, other blood products (e.g. fresh frozen (therapeutic) plasma), coagulations factors, and any other haemotherapy (including use of cell salvage

Countries

Germany

Contacts

Primary ContactKai D Zacharowski, Prof, MD, PhD
Direktion.Anaesthesie@kgu.de0049 69 6301
Backup ContactPatrick Meybohm, M.D
patientbloodmanagement@kgu.de0049 6906301

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026